NALIRIFOX in Combination With Camrelizumab for BRPC: a Prospective, Exploratory Study
Status:
RECRUITING
Trial end date:
2025-12-24
Target enrollment:
Participant gender:
Summary
The aim of this study is to assess the efficacy and safety of Liposomal Irinotecan, Oxaliplatin, 5-Fluorouracil/Calcium folinate in combination with Camrelizumab for patients with borderline resectable pancreatic cancer
Phase:
PHASE2
Details
Lead Sponsor:
Cancer Institute and Hospital, Chinese Academy of Medical Sciences